Dr. Helen Sabzevari is president of Precigen and is responsible for all aspects of the company’s leadership. Founded in 2017 as a wholly owned subsidiary of Intrexon (NASDAQ: XON), Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision immunology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious disease. Dr. Sabzevari was previously co-founder and chief scientific officer of Compass Therapeutics where she led discovery and early development for the company in the area of immuno-oncology and autoimmune diseases. Prior to Compass Therapeutics, Dr. Sabzevari was senior vice president of immuno-oncology at Merck Serono (a subsidiary of Merck KGaA), where she led the immune-oncology discovery and early development platform. Dr. Sabzevari is internationally recognized for her work in the field of immuno-oncology. Her contributions in the field of tumor immunology earned her the National Institutes of Health (NIH) merit award for major contribution to the field of cancer immunotherapy. She has been the Recipient of Mass High Tech’s Women to Watch Award and the PharmaVOICE 100 Award. Prior to joining Merck Serono, she served as head of the molecular immunology group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute (LTIB-NCI), where she led a translational research program with the goals of design, development and delivery of novel vaccines and immunotherapies for a range of human cancers. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases.